Experts say the future of biosimilars in the U.S. still looks hopeful, despite current roadblocks to their market entry. With Zarxio’s entry into the U.S. market still stalled by legal battles, many experts are still optimistic about the potential of biosimilars, especially in easing health care spending – once they enter the market, that … Continue reading Biosimilars Still Hold Cost-Cutting Promise Say Pundits
Read moreStakeholder Impact Study to Look at Oncology Biosimilars
Global medical market research company, Ipsos Healthcare in May launched a syndicated study to highlight the impact of biosimilars on treating cancer patients. Known as the Multi-Stakeholder Biosimilar Impact Study, it follows the firm’s successful launch of a 2014 syndicated Biosimilar Impact Study in the autoimmune field. The study has been developed in response … Continue reading Stakeholder Impact Study to Look at Oncology Biosimilars
Read moreLilly Poised to Launch Lantus Biosimilar in Europe
Following the patent expiry of Sanofi’s diabetes drug Lantus, Eli Lilly has announced it plans to launch its biosimilar version in Europe later this year. Global pharmaceutical company, Eli Lilly & Co., plans to launch its biosimilar version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter of 2015, president of … Continue reading Lilly Poised to Launch Lantus Biosimilar in Europe
Read moreWho’s Leading the Biosimilars Race?
US biopharma giants, Pfizer and Amgen, along with South Korea’s Celltrion are emerging as frontrunners in the biosimilars race While Sandoz/Novartis can claim victory with the first FDA biosimilar approval of Zarxio in March, it’s Pfizer, Amgen and Celltrion that have the volume of biosimilars in the pipeline Amgen, Pfizer and Novartis are wisely … Continue reading Who’s Leading the Biosimilars Race?
Read moreExpert Panel Discusses Biosimilars Impact
A panel of health industry leaders, hosted by the Alliance for Health Reform, gathered together representatives from Hospira, Amgen, the FDA and other industry experts to discuss the future of biosimilars in the U.S. Alliance executive vice president, Ed Howard, moderated the event, where expert panelists discussed the U.S. and global markets for reference … Continue reading Expert Panel Discusses Biosimilars Impact
Read morePrescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars
With Zarxio’s entry into the U.S. market still pending, pharmacists need to be aware of biosimilars in order to better assist their patients. While the U.S.’s first approved biosimilar, Zarxio is yet to be available to prescribers and patients amid ongoing legal battles, the fact is that biosimilars will soon be a reality … Continue reading Prescribers, Pharmacists and Patients: Negotiating the Issues Around Biosimilars
Read moreReport Reveals US Payer Perspectives on Biosimilars
A recent report offers payers’ insights into the U.S. biologics market, and the impact biosimilars will have on it. With spending on biologics set to reach $100 billion in the U.S. over the next couple of years, biosimilars are seen as a offering potential relief for healthcare system financial pressures of declining resources, increasing … Continue reading Report Reveals US Payer Perspectives on Biosimilars
Read moreWhat Do Doctors Think?
In March 2015, the Alliance for Safe Biologic Medicines (ASBM), released results from their survey of 400 US physicians on biologic medicines labelling. It found: In 2013, the ASBM also surveyed 470 European physicians, from the United Kingdom, France, Germany, Italy and Spain to gauge their views on non-proprietary naming of biological medicines. … Continue reading What Do Doctors Think?
Read moreStudy Finds Remicade Antibodies Cross-React with Remsima
An Israeli study found similar immune responses to the brand name and biosimilar infliximab among patients with inflammatory bowel disease. “The study [of 86 patients] found that patients with inflammatory bowel disease (IBD) who produce antibodies to infliximab when treated with Janssen’s Remicade also cross-react with Celltrion’s biosimilar, Remsima. One author of the study, Dr. … Continue reading Study Finds Remicade Antibodies Cross-React with Remsima
Read moreANVISA Approves First Infliximab Biosimilar in Brazil
The National Health Surveillance Agency (ANVISA) in Brazil has approved the use of the monoclonal antibody Remsima (infliximab) from Hospira Inc. and its partner Celltrion. Remsima is responsible for the treatment of, “rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn’s disease in adults and children, fistulizing Crohn’s disease (advanced), colitis and ulcerative rectocolitis.” This … Continue reading ANVISA Approves First Infliximab Biosimilar in Brazil
Read more